Time Therapeutics

The company is led by President and CEO Toshifumi Watanabe, who brought extensive experience from various high-level positions in the pharmaceutical industry, including roles at Takeda Pharmaceutical and Novartis Pharma, before taking the helm at Time Therapeutics. The company’s primary mission is the research, development, and marketing of medicines and medical devices for intractable diseases, with a significant focus on neurodegenerative conditions like Alzheimer's disease. Its core technology, named “iPSC-based Drug Discovery: from dish to bedside,” utilizes patient-derived iPSCs to more accurately predict the efficacy of drug compounds, precisely classify patient groups, and determine appropriate pricing. This method aims to streamline the drug discovery process, particularly for conditions where traditional models have been less effective.

Time Therapeutics' business model centers on advancing its pipeline of drug candidates and securing partnerships. The company's strategy involves short-term goals of entering joint R&D agreements with pharmaceutical companies to secure resources, and longer-term objectives that include establishing multiple clinical development pipelines and eventually obtaining marketing approval for its products. The company's pipeline includes candidates for Familial Alzheimer's Disease (TTM-001), Tauopathy (TTM-002), and ALS (TTM-003). Financially, Time Therapeutics has successfully raised a total of $23.6 million over four funding rounds, including two Seed and two Early-Stage rounds. Its largest round was a Series B for $12.8 million in June 2024, demonstrating continued investor confidence in its scientific platform and development strategy.